Home Science & Medicine Immunotherapy

Immunotherapy

Feature articles about current research in immunology that has significant impact or impact potential on thoracic oncology.

PD-L1 Blueprint Project

By Fred R. Hirsch, MD, PhD In the new era of immunotherapy in thoracic cancer, evaluating PD-L1 status remains a clinical challenge. In recognition of...

Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A New Paradigm Post-IASLC WCLC...

By Melody Watson The first plenary session on the last day of IASLC WCLC 2016 covered one of the most exciting areas in NSCLC research...

Changing Landscape of Front-line Immunotherapy

By Naiyer A. Rizvi The rapid development of anti-PD-1 and PD-L1 antibodies in cancer underscores the tremendous impact they have had on the cancer landscape...

PD-L1 IHC Blueprint Project” Presented at the AACR Annual Meeting 2016

By Erik J. MacLaren, PhD Immunotherapy with anti-PD-L1/PD-1 antibodies is rapidly changing the therapeutic landscape for patients with non-small cell lung cancer (NSCLC). However, selecting...

Update on Checkpoint Inhibitors in Lung Cancer

By Erik J. MacLaren, PhD The growing number of checkpoint inhibitors currently being developed, without question, has ushered in a new era in clinical oncology,...

Meeting News